NICE recommends faecal immunochemical tests for colorectal cancer to reduce waiting time for colonoscopies


Share post:

National Institute for Health and Care Excellence (NICE)’s diagnostic advisory committee has recommended the use of HM-JACKarc or OC-Sensor quantitative faecal immunochemical tests (FIT) in a draft guidance release for consultation on Wednesday (5 July).

Under existing NICE guidance, FIT was already offered to some people presenting to primary care with symptoms suggestive of colorectal cancer, while others were immediately referred on the suspected cancer pathway.

The new draft guidance will now see everyone receive a FIT.

A sample is sent in the post to a laboratory where the amount of blood in the faeces is measured. The results are usually available within a week and people with 10 or more micrograms of haemoglobin in their faeces should then be referred for further investigation.

Further assessment using colonoscopy, or CT colonography, is required to diagnose cancer.

The tests cost between £4 and £5 per sample, and can correctly identify about 9 out of 10 people with colorectal cancer.

The committee agreed it is important that GPs can refer people for colonoscopy without a positive FIT result if they think it is necessary and where symptoms persist.

The institute believes that the recommendation of the tests should reduce the number of unnecessary colonoscopies, thus freeing up appointments for more non-urgent referrals. This should lead to 50% fewer referrals for urgent colonoscopies being made by GPs in primary care settings each year.

There are 42,000 new cases of colorectal cancer each year according to Cancer Research UK.

Mark Chapman, interim director of medical technology and digital evaluation at NICE, said: “Colorectal cancer is the fourth most common cancer in the UK and ensuring people receive a fast diagnosis must be a priority to allow treatment to get started as soon as possible.

“We know the demand for colonoscopies is high, so recommending the use of FIT in primary care could identify people who are most likely to have a condition that would be detected by colonoscopy.

“Introducing FIT to people as an initial test will also mean that those who are unlikely to have colorectal cancer may avoid having a colonoscopy, and those who are more likely to have it can be prioritised. We hope this will reduce waiting times because fewer people will be receiving a colonoscopy they don’t need.

“These recommendations ensure we are balancing the best care with value for money, while at the same time delivering both for individuals and society as a whole.”

A consultation has now begun on the committee’s recommendations via until Wednesday 19 July 2023. 


Please enter your comment!
Please enter your name here

Current Issue June 2023

Related articles

A new Haleon report claims growth of pain in the past decade

Consumer health company Haleon, formerly known as GSK, claims that pain's emotional and life impact has grown by...

Viatris to divest some businesses for nearly £3 billion

Drugmaker Viatris said on Sunday (October 1) it had reached agreements to divest some of its businesses for...

Titan PMR set to unveil ‘Titanverse’, a one-stop-shop tech solution for pharmacy businesses

Bristol-based Titan PMR, a technology firm specialising in PMR systems for community pharmacies, is set to roll out...

Six Scotland-based pharmacists recognised at celebratory RPS event in Edinburgh

Six pharmacists based in Scotland were acknowledged by the profession this week during a celebratory event held at...